67,600 Shares in Exagen Inc. $XGN Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI purchased a new stake in shares of Exagen Inc. (NASDAQ:XGN) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 67,600 shares of the company’s stock, valued at approximately $472,000. Citizens Financial Group Inc. RI owned about 0.31% of Exagen as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of XGN. Calamos Advisors LLC acquired a new stake in shares of Exagen during the second quarter worth about $526,000. Huntleigh Advisors Inc. raised its position in Exagen by 5.7% during the 2nd quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company’s stock worth $613,000 after buying an additional 4,753 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Exagen during the 1st quarter valued at approximately $25,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Exagen by 45.6% in the 2nd quarter. Geode Capital Management LLC now owns 146,483 shares of the company’s stock valued at $1,023,000 after acquiring an additional 45,884 shares during the last quarter. 75.25% of the stock is owned by institutional investors and hedge funds.

Exagen Price Performance

Exagen stock opened at $8.21 on Wednesday. The company’s fifty day moving average price is $10.59 and its 200 day moving average price is $8.73. Exagen Inc. has a 1 year low of $2.67 and a 1 year high of $12.23. The stock has a market capitalization of $186.04 million, a P/E ratio of -8.92 and a beta of 1.66. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08.

Exagen (NASDAQ:XGN) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $17.24 million for the quarter, compared to analysts’ expectations of $16.90 million. Exagen had a negative return on equity of 113.48% and a negative net margin of 29.94%. Exagen has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Exagen Inc. will post -0.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

XGN has been the subject of several recent research reports. B. Riley reissued a “buy” rating and set a $18.00 target price (up previously from $15.00) on shares of Exagen in a report on Wednesday, November 5th. Canaccord Genuity Group lifted their price objective on Exagen from $11.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Craig Hallum initiated coverage on Exagen in a report on Wednesday, July 23rd. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exagen in a report on Wednesday, October 8th. Finally, BTIG Research lifted their price target on Exagen from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.17.

Insiders Place Their Bets

In other Exagen news, CEO John Aballi sold 31,787 shares of the company’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $11.82, for a total value of $375,722.34. Following the completion of the sale, the chief executive officer directly owned 714,427 shares in the company, valued at $8,444,527.14. This represents a 4.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 12.60% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).